DCTH

$9.74

Post-MarketAs of Mar 17, 8:00 PM UTC

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$9.74
Potential Downside
86.6%
Whystock Fair Value$1.30
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Devices

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delive...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$343.96M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
139.14
Beta
Defensive asset. Lower volatility than the S&P 500.
0.47
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
3.00%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
9.43

Recent News

TipRanks
Mar 4, 2026

Delcath Systems publishes results from CHOPIN trial in The Lancet Oncology

Delcath Systems (DCTH) announced the publication of the full results from the investigator-initiated CHOPIN randomized Phase 2 clinical trial, led by Principal Investigator Professor Ellen Kapiteijn from Leiden University Medical Center’s Department of Medical Oncology. The publication, titled “Percutaneous hepatic perfusion combined with ipilimumab and nivolumab for metastatic uveal melanoma: a single-centre, open-label, randomised, phase 2 trial” is published in The Lancet Oncology and present

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
GuruFocus.com
Feb 26, 2026

Delcath Systems Inc (DCTH) Q4 2025 Earnings Call Highlights: Record Revenue and Strategic ...

Delcath Systems Inc (DCTH) reports record annual revenue of $85.2 million, outlines 2026 growth strategies, and addresses challenges in R&D expenses and seasonal impacts.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Feb 26, 2026

Delcath Systems Q4 Earnings Call Highlights

Delcath Systems (NASDAQ:DCTH) reported record results for 2025 and outlined a commercial and clinical roadmap that management believes can support continued growth, emphasizing expanding treatment-center capacity, increasing new patient starts, and strengthening referral networks. On the company’s f

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Feb 26, 2026

Delcath (DCTH) Q4 2025 Earnings Call Transcript

Need a quote from a Motley Fool analyst? David Hoffman: With me on the call are Gerard Michel, Chief Executive Officer; Sandra Pennell, Chief Financial Officer; Kevin Muir, General Manager, Interventional Oncology; Vojislav Vukovic, Chief Medical Officer; and Martha Rook, Chief Operating Officer.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Moby
Feb 26, 2026

Delcath Systems, Inc. Q4 2025 Earnings Call Summary

Moby summary of Delcath Systems, Inc.'s Q4 2025 earnings call

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.